skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes

Journal of clinical medicine, 2019-06, Vol.8 (6), p.864 [Peer Reviewed Journal]

2019 by the authors. 2019 ;ISSN: 2077-0383 ;EISSN: 2077-0383 ;DOI: 10.3390/jcm8060864 ;PMID: 31212945

Full text available

Citations Cited by
  • Title:
    The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes
  • Author: García-Carro, Clara ; Vergara, Ander ; Agraz, Irene ; Jacobs-Cachá, Conxita ; Espinel, Eugenia ; Seron, Daniel ; Soler, María José
  • Subjects: diabetes ; diabetic kidney disease ; dipeptidyl peptidase 4 inhibitors ; glucagon-like peptide-1 receptor agonists ; reno-cardiovascular protection ; Review ; sodium-glucose co-transporter 2 inhibitors
  • Is Part Of: Journal of clinical medicine, 2019-06, Vol.8 (6), p.864
  • Description: Diabetic kidney disease (DKD) is the leading cause of end-stage renal disease in the developed world. Until 2016, the only treatment that was clearly demonstrated to delay the DKD was the renin-angiotensin system blockade, either by angiotensin-converting enzyme inhibitors or angiotensin receptor blockers. However, this strategy only partially covered the DKD progression. Thus, new strategies for reno-cardiovascular protection in type 2 diabetic patients are urgently needed. In the last few years, hypoglycaemic drugs, such as sodium-glucose co-transporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, demonstrated a cardioprotective effect, mainly in terms of decreasing hospitalization for heart failure and cardiovascular death in type 2 diabetic patients. In addition, these drugs also demonstrated a clear renoprotective effect by delaying DKD progression and decreasing albuminuria. Another hypoglycaemic drug class, dipeptidyl peptidase 4 inhibitors, has been approved for its use in patients with advanced chronic kidney disease, avoiding, in part, the need for insulinization in this group of DKD patients. Studies in diabetic and non-diabetic experimental models suggest that these drugs may exert their reno-cardiovascular protective effect by glucose and non-glucose dependent mechanisms. This review focuses on newly demonstrated strategies that have shown reno-cardiovascular benefits in type 2 diabetes and that may change diabetes management algorithms.
  • Publisher: Switzerland: MDPI
  • Language: English
  • Identifier: ISSN: 2077-0383
    EISSN: 2077-0383
    DOI: 10.3390/jcm8060864
    PMID: 31212945
  • Source: PubMed Central
    Directory of Open Access Journals
    ROAD: Directory of Open Access Scholarly Resources
    ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait